http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2026-02-06 12:01:062026-02-10 12:01:56Scrip Asks… What Does 2026 Hold For Biopharma?
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2026-01-09 16:46:472026-01-21 16:47:59Eyes, mitochondria and a growing hub
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2025-12-03 16:10:232026-01-21 17:07:55Vandria announces topline results from Phase I trial of VNA-318
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2025-12-02 16:30:392026-01-21 17:08:52Swiss biotech plots Series B raise to advance Alzheimer’s drug into Phase 2
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2025-12-02 16:25:082026-01-21 17:08:38Vandria’s phase I data offer new mode of action in Alzheimer’s
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2025-12-02 16:20:192026-01-21 17:08:23Vandria reports VNA-318’s first-in-human data in Alzheimer’s
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2025-12-02 16:15:282026-01-21 17:08:07Vandria advances positive Phase I data and eyes 2026 series B
http://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svg00Webadnhttp://preview.vandria.com/wp-content/uploads/2025/11/Vandria-Logo-RGB-Color.svgWebadn2025-12-02 16:05:482026-01-21 17:07:42Vandria reports positive phase 1 data for Alzheimer’s drug candidate
